GSK plc (GSK) Balance Sheet

The alternating pattern of asset size, with peaks in Q1 and Q3, suggests that GSK's balance sheet is influenced by timing of acquisitions and divestitures, possibly related to the Haleon spin-off and bolt-on deals. Equity has grown from $13.7B in 2024Q4 to $17.5B in 2026Q2, indicating retained earnings accumulation despite volatility. This trajectory implies a stable but not rapidly strengthening balance sheet, consistent with the prior income statement's stable growth signal.

The reduction in D/E from 1.34 to 1.06 over five quarters indicates that GSK is paying down debt or growing equity faster, likely through retained earnings. However, the absolute debt level of $18.1B is still high relative to cash of $3.1B, implying a reliance on debt for funding operations and acquisitions. This leverage is typical for large pharma, but the low current ratio of 0.82 suggests potential liquidity pressure, though the company's cash flow generation appears robust.

The presence of substantial PPE underscores GSK's asset-heavy model, particularly in vaccine and biologic production, which requires specialized facilities. Goodwill of $7.3B, though down from $9.6B in 2026Q1, still represents a meaningful portion of assets, suggesting that past acquisitions have not been fully impaired. The fluctuation in goodwill across quarters may reflect acquisitions and divestitures, warranting monitoring for potential impairment if growth expectations falter.

The steady increase in retained earnings, despite occasional net losses, indicates that GSK is consistently generating profits and reinvesting them. This growth in equity, from $13.7B to $17.5B, strengthens the balance sheet and provides a buffer against potential litigation charges. However, the equity base is still relatively small compared to total assets, implying a high leverage ratio, which may concern investors seeking financial stability.

A current ratio below 1 suggests that GSK may struggle to cover short-term obligations with current assets alone, though this is common in pharma where cash flows are strong. Cash of $3.1B is modest relative to debt, but the company's operating cash flow has been robust, averaging over $1.8B per quarter, which provides a cushion. The low current ratio may reflect efficient working capital management or timing of payables, but investors should monitor for any deterioration in cash generation.